Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease.
North America market for nuclear medicine Radiopharmaceuticals is estimated at $2.23 billion in 2018 and is expected to reach $3.79 billion by 2023, growing at a CAGR of 11.2%.
Increasing incidence of chronic diseases such as cancer and cardiac ailments, huge technological advancements, escalating demand for SPECT and PET applications along with the growing public awareness for healthcare are the major factors fuelling the growth of Radiopharmaceuticals market. Further, Integration of X ray tomography (CT) into SPECT has recently emerged as an excellent diagnostic tool in medical imaging and is considered to be a driving factor for the growth of the market. Strict regulatory framework and reimbursement issues are the key factors blocking the growth of the market. In addition to the above factors shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are also the key factors restraining the North America nuclear medicine Radioisotopes market.
The market of radiopharmaceuticals is segmented into Diagnostic radioisotopes and Therapeutic radioisotopes. Diagnostic radioisotope market basically covers SPECT (Technetium-99m, Thallium-201 Gallium-67, Iodine) and PET (Fluorine-18, Rubidium-82) radioisotopes. Therapeutic radioisotopes cover Beta emitters (Iodine-131, Yttrium-90, Samarium-153, Rhenium-186, Lutetium-177), Alpha Emitters (Radium-223) and Brachytherapy (Cesium-131, Iodine-125, Palladium-103, Iridium-192). By application market is segmented into (cardiology, lymphoma, thyroid, neurology oncology, and others). Furthermore, on the basis of geography, the North America market is analyzed two regions namely, USA and Canada.
Radiopharmaceuticals market is dominated by diagnostic radioisotopes with an estimated market share of 90 % while therapeutic radioisotopes contribute for around 10% of the market. Based on type of radioisotopes the market is segmented into Technetium-99m (TC-99m), Thallium-201 (TL-201), Fluorine-18, Iodine (I-123), Rubidium-82 (RB-82) and others. The F-18 market is mostly contributed by F-18 FDG tracers though this market is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcomes of these tracers have gained the business interest of major research institutes and PET isotope players. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic market, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes market. United States is the largest consumer market for radioisotopes and Canada is the largest producer of Tc-99m.
Some of the key players influencing the North America nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation,Positron Corporation,Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Diagnostic Radioisotopes
5.1.1.1 SPECT
5.1.1.1.1 Technetium-99m
5.1.1.1.2 Thallium-201
5.1.1.1.3 Gallium-67
5.1.1.1.4 Iodine-23
5.1.1.1.5 Others
5.1.1.2 PET
5.1.1.2.1 Fluorine-18
5.1.1.2.2 Rubidium-82
5.1.1.2.3 Others
5.1.2 Therapeutic Radioisotopes
5.1.2.1 Beta Emitters
5.1.2.1.1 Iodine-131
5.1.2.1.2 Yttrium-90
5.1.2.1.3 Samarium-153
5.1.2.1.4 Rhenium-186
5.1.2.1.5 Lutetium-177
5.1.2.2 Alpha Emitters
5.1.2.2.1 Radium-223
5.1.2.3 Brachytherapy
5.1.2.3.1 Cesium-131
5.1.2.3.2 Iodine-125
5.1.2.3.3 Palladium-103
5.1.2.3.4 Iridium-192
5.2 By Application
5.2.1 Cardiology
5.2.2 Lymphoma
5.2.3 Thyroid
5.2.4 Neurology
5.2.5 Oncology
5.2.6 Others
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Hologic Inc.
8.3 Segami Corporation
8.4 Positron Corporation
8.5 Bracco Imaging S.P.A
8.6 Naviscan Inc.
8.7 Bayer Healthcare
8.8 Lantheus Medical Imaging Inc.
8.9 IBA Molecular Imaging
8.10 Medix Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
